Document:

Exhibit 10.31.2

 

AMENDMENT TO RETAINED INTELLECTUAL PROPERTY
LICENSE

AGREEMENT DATED MARCH 31, 2005 BY AND BETWEEN

BAYER HEALTHCARE LLC (“LICENSOR”)

AND TALECRIS BIOTHERAPEUTICS, INC. (“LICENSEE”)

 

Whereas Licensor and Licensee have entered
into a Retained Intellectual Property License Agreement dated March 31, 2005 (“the
License Agreement”) wherein Licensor granted Licensee a license under certain
intellectual property rights called Retained Intellectual Property limited to
the Field as defined therein;

 

Whereas the License Agreement only gives
Licensee the right to sublicense the intellectual property rights to Affiliates
that are subsidiaries;

 

Whereas Bayer Corporation (predecessor in
interest to Bayer Pharmaceuticals Corporation) entered into a Technology
Transfer Agreement (“TTA”) with the Japanese Red Cross Society (the “JRC”)
dated October 29, 2002, under which the JRC was granted certain exclusive
rights relating to Japanese Patent Application No. 265084/96 (counterpart to US
Patent No. 6,686,191) and any patents issuing therefrom (the “Japanese Patent
Rights”), but without the right to grant sublicenses; which TTA has been
assigned by Licensor to Licensee;

 

Whereas Licensee desires, as part of the
agreed terms of settlement to a litigation styled “Talecris Biotherapeutics,
Inc. and Bayer HealthCare LLC v. Baxter International Inc. and Baxter
Healthcare Corporation” [Delaware Federal District Court Civil Action No.
05-349-GMS] to grant to Baxter International Inc. and Baxter Healthcare
Corporation and their Affiliates (Baxter International Inc., Baxter Healthcare
Corporation and their Affiliates shall be referred to herein, jointly and
severally, as “Baxter”) a worldwide sublicense to certain intellectual property
rights within the Retained Intellectual Property;

 

Whereas Licensor agrees to grant Licensee a
limited, non-assignable, non-transferable worldwide right to sublicense to
Baxter the license rights granted to Licensee under the License Agreement with
respect to certain of the intellectual property rights within the Retained
Intellectual Property (the “Sublicense Agreement”), under the terms and
conditions set forth herein;

 

Whereas Licensor agrees to grant Licensee a
limited right to amend the TTA to grant the JRC the right to grant a sublicense
to Baxter; and

 

Whereas Licensor and Licensee have agreed to
amend the License Agreement in accordance with the terms and conditions set
forth in this Amendment;

 

Now, therefore, Licensor and Licensee,
intending to be bound, agree to amend the License Agreement as follows (the “Amendment”):

 

ARTICLE I - GRANT OF
SUBLICENSE BY LICENSEE TO BAXTER

 

1.1           Subject to the terms and conditions
of this Amendment and the License Agreement, and notwithstanding the
restrictions on Licensee’s right to sublicense in Section 2.1 of the License
Agreement, Licensor grants to Licensee a non-transferable, non-assignable right
to grant to Baxter a worldwide perpetual non-exclusive sublicense to the
intellectual property identified in attached Exhibit A (“Baxter Sublicense IP”),
but only to allow Baxter to make, have made, use, have used, offer to sell,
sell, have sold, import, and have imported its commercially marketed Gammagard®
product and/or other liquid IGIV products and/or plasma derived immunoglobulin
products made using the Baxter Sublicense IP, provided, however, that
recombinant products

 

 

and Recombinant
Hemophilia Products (as defined in the License Agreement) are not within the
scope of this grant and this Amendment.

 

1.2           “Affiliate” shall mean a corporation,
company, or other entity 50 percent (50%) or more of whose outstanding shares
or securities (representing the right, other than as affected by events of
default, to vote for the election of directors or other managing authority)
are, now or hereafter, owned or controlled, directly or indirectly, by a party
hereto, but such corporation, company, or other entity shall be deemed to be an
Affiliate only so long as such ownership or control exists.

 

ARTICLE II - GRANT OF
SUBLICENSE TO THE JAPANESE PATENT RIGHTS TO BAXTER

 

2.1           Licensor hereby consents to Licensee
amending the TTA to permit Licensee or the JRC to grant a sublicense to Baxter
relating to the Japanese Patent Rights, thereby converting the JRC license from
an exclusive to a non-exclusive license to that extent. Any right granted under
this Section 2.1 shall be limited to the Japanese Patent Rights, shall be on
terms including those set forth below in Article III, and shall be only to
allow Baxter to make, have made, use, have used, offer to sell, sell, have sold,
import, and have imported its commercially marketed Gammagard ® liquid product
and/or other liquid IVIG products and/or plasma derived immunoglobulin products
made using the Japanese Patent Rights, but excluding recombinant products and
Recombinant Hemophilia Products.

 

ARTICLE III - GENERAL
TERMS

 

3.1           Licensee’s right to grant a
sublicense to Baxter or authorize the JRC to grant a sublicense to Baxter, is
personal in nature, and Baxter shall not be granted any right to sublicense,
assign, or otherwise transfer any of the sublicensed rights.

 

3.2           Any grant of a sublicense to Baxter
by Licensee shall be subject to the terms and conditions of the License
Agreement. Any grant of a sublicense by the JRC shall be subject to the terms
of the TTA. All such sublicenses shall be in writing and shall contain the
provisions of Paragraphs 3.7-3.9 of this Amendment, or their equivalent. Licensee
shall remain primarily liable to Licensor for Baxter’s performance under any
sublicense. Inclusion of the terms and conditions required by this Agreement is
an express condition precedent to Licensee’s right to grant a sublicense, and
Licensee’s right to authorize the JRC to grant a sublicense to Baxter under
this Agreement, and any writing that purports to grant a sublicense to Baxter
but does not include the required terms shall be void and shall not be
effective unless and until all such required provisions terms are included.

 

3.3           Licensee shall provide to Licensor a
copy of any writing granting a sublicense to Baxter within thirty (30) days of
the effective date or date of execution of any such writing, whichever occurs
earlier.

 

3.4           No other rights or licenses, express
or implied, are granted or shall be deemed to be granted under this Amendment
other than those rights and licenses expressly granted herein.

 

3.5           The parties hereto, intending to be
legally bound, and for the use and benefit of Baxter, hereby agree that in the
event (1) Licensee materially defaults under the License Agreement as amended
or the Sublicense Agreement; or (2) the License Agreement as amended or the
Sublicense Agreement is rescinded or set aside in the event of bankruptcy or
insolvency proceedings, then and in that event, Licensor agrees to grant and to
have granted to Baxter a license on terms consistent with the rights and
obligations of Licensee and Sublicensee in the Sublicense Agreement, subject to
any pre-existing rights of third parties as set forth in the

 

2

 

License Agreement;
provided, however, that the grant by Licensee to Baxter in the Sublicense
Agreement of rights to the Japanese Patents Rights shall not constitute a
material default.

 

3.6           Licensee agrees to indemnify,
release, and hold harmless Licensor, its affiliates, subsidiaries, and their
respective directors, officers, employees and agents from and against any
liabilities, losses, fines, penalties, damages, expenses (including reasonable
attorney’s fees and expenses incurred in connection with the enforcement of
this provision), actions, or claims brought or threatened by or against the
JRC, or brought or threatened against Licensee or Baxter, or their respective
Affiliates, that arise out of, or relate to this Amendment, the rights or
licenses granted under this Amendment or in accordance with this Amendment, the
Baxter Sublicense IP, any grant of a sublicense to Baxter, or any agreement
with the JRC (if applicable) or Baxter that relates to the Baxter Sublicense IP.
It is Licensee’s obligation to obtain appropriate indemnification from JRC (if
applicable) and/or Baxter if it so desires.

 

3.7           Licensor and Licensee acknowledge
that this Amendment is being executed in conjunction with the final settlement
of a lawsuit between Licensee and Baxter concerning patents that Licensor has
licensed to Licensee under the License Agreement. To the extent such obligation
is permitted to be imposed by applicable law, Licensee hereby covenants and
will cause Baxter to covenant, not to directly or indirectly contest or to
assist any other person or party to contest the validity or enforceability of
the Baxter Sublicense IP, except if Baxter’s right to a license to the Japanese
counterpart to the ‘191 Patent, whenever issued, is challenged. In that
instance, Baxter maintains the right to contest, and may contest, the validity
or enforceability of the Japanese counterpart to the ‘191 Patent, whenever
issued.

 

3.8           THE RIGHTS AND LICENSES GRANTED BY
THIS AMENDMENT, AND ANY GRANT BY LICENSEE OF A SUBLICENSE IN ACCORDANCE WITH
THE TERMS OF THIS AMENDMENT, ARE GRANTED WITH NO WARRANTIES OF ANY KIND. LICENSOR
MAKES, AND LICENSEE SHALL MAKE NO WARRANTIES OR REPRESENTATIONS (EXPRESS,
IMPLIED, STATUTORY, ARISING OUT OF A COURSE OF DEALING OR USAGE OF TRADE OR
OTHERWISE) WITH RESPECT TO ANY OF THE RIGHTS GRANTED BY THIS AMENDMENT, ANY
SUBLICENSE RIGHTS GRANTED PURSUANT TO THIS AMENDMENT, OR THE BAXTER SUBLICENSE
IP. LICENSOR SPECIFICALLY DISCLAIMS, AND LICENSEE SHALL DISCLAIM IN ANY
AGREEMENT WITH BAXTER OR THE JRC, ANY AND ALL IMPLIED WARRANTIES OR
REPRESENTATIONS CONCERNING NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS
OF OTHERS, OR THE MERCHANTABILITY, MERCHANTABLE QUALITY, FITNESS OR ADEQUACY
FOR ANY PARTICULAR PURPOSE OR USE OF THE BAXTER SUBLICENSE IP, ANY RIGHTS
GRANTED BY THIS AMENDMENT, ANY EXERCISE OF THE RIGHTS GRANTED BY THIS AMENDMENT
BY LICENSEE, ANY RIGHTS GRANTED BY LICENSEE TO BAXTER IN ACCORDANCE WITH THIS
AMENDMENT, OR ANY EXERCISE OF ANY RIGHTS GRANTED BY LICENSEE TO THE JRC OR
BAXTER IN ACCORDANCE WITH THIS AMENDMENT. NOTHING IN THIS AMENDMENT SHALL BE
CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY LICENSOR THAT ANY
ACTIVITY ENGAGED IN BY LICENSEE OR BAXTER, OR THE EXERCISE OF ANY RIGHTS
GRANTED IN THIS AMENDMENT, OR OF ANY RIGHTS GRANTED BY LICENSEE OR THE JRC TO
BAXTER IN ACCORDANCE WITH THIS AMENDMENT, WILL NOT INFRINGE THE PATENT OR OTHER
INTELLECTUAL PROPERTY RIGHTS OF ANY PERSON OR ENTITY OTHER THAN LICENSOR.

 

3.9           IN NO EVENT SHALL LICENSOR BE LIABLE
TO LICENSEE OR TO BAXTER, OR THEIR RESPECTIVE AFFILIATES, FOR ANY LOSS OF PROFITS,
LOSS OF BUSINESS OR INTERRUPTION OF BUSINESS, OR FOR ANY OTHER INDIRECT,
SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OF ANY KIND,

 

3

 

EVEN IF LICENSOR HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGES. IN NO CASE SHALL LICENSOR
BE LIABLE FOR ANY REPRESENTATION OR WARRANTY MADE BY LICENSEE OR BAXTER TO ANY
THIRD PARTY.

 

3.10         This amendment is a mutually agreed
amendment to the License Agreement, and contains the entire agreement between
the parties with regard to the matters dealt with herein and no
representations, terms, conditions or warranties not contained herein shall be
binding on the parties.

 

3.11         No amendment varying, adding to,
deleting from or canceling this Amendment shall be effective unless reduced to
writing and signed by or on behalf of the parties.

 

3.12         No waiver by either party of any breach
of this Amendment shall be a waiver of any preceding or succeeding breach. No
waiver by a party of any right under this Amendment shall be construed as a
waiver of any other right.

 

3.13         Neither this Amendment nor any right or
obligation herein may be assigned or delegated by Licensee, including by sale,
merger, operation of law or otherwise, without the express prior written consent
of Licensor. Any attempted assignment or delegation not in conformity herewith
shall be null and void or voidable.

 

3.14         If any provision of this Amendment is
for any reason held invalid or illegal in any respect, such illegality shall
not affect the validity of this Amendment itself and there shall be substituted
for the affected provision a valid and enforceable provision that most closely
approximates the intent and economic effect of the invalid provision. If such
provision cannot be amended so as to be valid and enforceable, then such
provision is severable for this Amendment and the remaining provisions of this
Amendment shall remain valid and enforceable.

 

3.15         To the extent that there is any
conflict between the express provisions of this Amendment and any of the
express terms of the License Agreement, the terms of this Amendment shall take
precedent.

 

3.16         This Agreement may be executed in
counterparts, which, when taken together, shall constitute one instrument.

 

4

 

IN WITNESS
WHEREOF, the parties have caused this Amendment to be duly executed by their
authorized representatives as set forth below:

 

BAYER HEALTHCARE LLC

 

 

	
  Signed:

  	
  /s/ JEFFREY M. GREENMAN

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
  Jeffrey M. Greenman

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  General Counsel & Secretary

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Date:

  	
  August 10, 2007

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  TALECRIS BIOTHERAPEUTICS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Signed:

  	
  /s/ RANDALL A. JONES

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
  Randall A. Jones

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  Senior Vice President

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Date:

  	
  August 10, 2007

  	
   

  
							

 

5Exhibit 10.34.2

 

Execution Copy

 

AMENDMENT TO

 

DISTRIBUTION AGREEMENT

 

FOR EUROPE

 

This Amendment
to the Distribution Agreement for Europe (this “Amendment”) is entered into as
of April 1, 2006 by and between Talecris Biotherapeutics, Inc. (“Talecris”), Bayer
Healthcare LLC (“Bayer”), Bayer Biologicals S.r.l. (“B.Biologicals”) and the
Distributors listed in Section 2 below (collectively, the “Distributors”). Capitalized
terms used and not otherwise defined herein shall have the meanings ascribed to
such terms in the Original Agreement (as defined below). Talecris, Bayer,
B.Biologicals and the Distributors are sometimes referred to herein
collectively as the “Parties,” and individually as a “Party.”

 

WHEREAS,
Bayer, Talecris, Talecris Holdings LLC (f/k/a NPS Bio Holdings, LLC), a limited
liability company organized under the laws of the state of Delaware, and
Talecris Biotherapeutics Holdings Corp., a corporation organized under the laws
of the state of Delaware, entered into that certain Amended and Restated Joint
Contribution Agreement, dated as of March 30, 2005 (the “Joint Contribution
Agreement”), to provide for, among other things, the contribution by Bayer
to Talecris of assets of the Plasma Business as described therein;

 

WHEREAS,
The parties entered into that certain Distribution Agreement, dated as of March
31, 2005 (the “Original Agreement”);

 

WHEREAS,
The Parties desire to amend the Original Agreement to extend its term with
respect to the Distributors.

 

NOW,
THEREFORE, for and in consideration of the premises and the mutual covenants
contained herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as
follows:

 

1.                                       Effective
Date. This Amendment shall be effective as of April 1, 2006 and the changes
made to the Original Agreement agreed to below shall apply beginning on such
date. Prior to that date, the terms of the Original Agreement shall continue to
govern.

 

2.                                       Distributors
Being Extended. Only the following Distributors in the following countries
are being extended and for the period of the Extended Term (defined below) any
reference to a “Distributor” under the Original Agreement shall mean only the
following:

 

	
  Bayer Entity

  	
   

  	
  Country

  
	
   

  	
   

  	
   

  
	
  Bayer S.A. - NY.

  	
   

  	
  Belgium

  
	
  Bayer Hellas AG

  	
   

  	
  Greece

  
	
  Bayer S.p.A.

  	
   

  	
  Italy

  
	
  Bayer Norge AS

  	
   

  	
  Norway

  
	
  Bayer Portugal AS

  	
   

  	
  Portugal

  
	
  Bayer (Schweiz)

  	
   

  	
  Switzerland

  
	
  Bayer AB

  	
   

  	
  Sweden

  
	
  Bayer Public Limited Company

  	
   

  	
  United Kingdom

  
	
  Bayer Gesellschaft m.b.H.

  	
   

  	
  Austria

  
	
  Quimicas Farmaceutica Bayer, S.A.

  	
   

  	
  Spain

  
	
  Bayer Oy

  	
   

  	
  Finland

  
	
  Bayer Denmark A/S

  	
   

  	
  Denmark

  
	
  Bayer Vital GmbH

  	
   

  	
  Germany

  

 

 

All of the
other entities, if any, that served as Distributors under the Original
Agreement shall cease to be Distributors as of the end of the term of the
Original Agreement (March 31, 2006).

 

3.                                       Term.

 

(a)                                  The
term under the Original Agreement shall be extended until March 31, 2007 (the “Term”);
provided, however, that Talecris may terminate any Distributor prior to that
date upon six (6) months’ prior written notice given in accordance with Section
20.3 of the Original Agreement (the “Distributor Extended Term”); provided
further that the termination date given in any such notice may only be the last
day of a calendar month. For the avoidance of doubt, each notice of termination
will necessarily be contingent on final action of the responsible regulatory
authorities. In the event that required transfer of market authorization or
other necessary regulatory approvals cannot be secured prior to the end of any
Distributor Extended Term, upon the written request of Talecris, Talecris (or
its designee) shall become an authorized sub-distributor of Distributor upon
Distributor’s approval and consent, which shall not be unreasonably withheld.

 

4.                                       Volume
Requirements. Exhibit B of the Original Agreement is hereby amended
and replaced in its entirety with Exhibit A attached hereto, with the
amounts reflected thereon to be the “Required Amount” for each Distributor for
the Extended Term; provided however, that in the event that Talecris terminates
a Distributor prior to March 31, 2007 that Distributor shall have no obligation
to purchase its Required Amount of Product for the period from the end of the
Distributor Extended Term to March 31, 2007, calculated by multiplying such Required
Amount by a fraction, the numerator of which is the number of months remaining
in the Term after termination and the denominator of which is twelve (12).

 

5.                                       Forecasts.
The forecasts provided for in Section 2.3(i) of the Original Agreement shall be
for rolling forecasts consisting of the number of months remaining in the
Distributor Extended Term.

 

6.                                       Support
for Commercial Activities. If Talecris terminates a Distributor prior to
March 31, 2007, that Distributor shall provide the level of support required
under Section 3(iii) of the Original Agreement for the duration of the
Distributor Extended Term.

 

7.                                       Benchmark
Price. Exhibit A of the Original Agreement is hereby amended and
replaced in its entirety with Exhibit A attached hereto, with the prices
reflected thereon to be the “Benchmark Prices” for each Product in each country
beginning April 1, 2006.

 

8.                                       Actual
Distributor Margin Adjustment. If a Distributor is terminated by Talecris
prior to March 31, 2007, notwithstanding anything in Section 5.5 to the
contrary, for the purposes of the calculations in Section 5.5(ii) of the
Original Agreement with respect to that Distributor the provisions of Section
5.5(i) shall not apply and the Actual Distributor Margin shall be six percent
(6%) plus one percent (1%) for working capital.

 

9.                                       Promotion
and Information Expenditures. If Talecris terminates a Distributor prior to
March 31, 2007, that Distributor shall spend the amounts on P&I required
under Sections 6.1(ii) and 6.1(iii) of the Original Agreement for the duration
of the Distributor Extended Term provided that P&I shall be prorated by
multiplying P&I by a fraction, the numerator of which is the number of
months in the Distributor Extended Term hereunder divided by twelve (12).

 

10.                                 Adjustment
to Fixed SG&A Costs and Committed, Actual P&I Costs. If Talecris
terminates a Distributor prior to March 31, 2007, such Distributor’s
reimbursement for fixed SG&A costs and committed, actual P&I costs
shall be adjusted pursuant to Section 6.1(iv) of the

 

2

 

Original
Agreement on a pro rata 12 month basis for the number of months constituting
the Extended Distributor Term.

 

11.                                 Bayer
Vital Employees. Talecris shall offer employment to the employees listed in
Annex 1 (attached hereto), such employment to commence upon the termination of
Bayer Vital’s status as a Distributor. All offers of employment shall be at
comparable or higher rate of base salary, wages and/or commissions and for a
comparable job position, as an existence on the effective date of such
termination and comply with the obligations of local law, if any. Upon
execution of this Amendment by Talecris and Bayer, Bayer shall cause to be
delivered to Talecris complete and true copies of the individual employment
contracts for each of the employees listed in Annex 1. Talecris shall assume
the obligations under such contracts from and after the date of transfer of any
such employees to Talecris and shall assume any accrued pension obligations as
to those employees who become employees of Talecris, in each case upon the
termination of Bayer Vital’s status as a Distributor (the “Assumed Obligations”).
Bayer and Talecris shall negotiate in good faith to reach an agreement to
reimburse Talecris for any accrued pension obligations assumed by Talecris as a
result of employing these and any other Bayer employees upon termination of
Bayer Vital’s status as a Distributor.

 

12.                                 Regulatory
and Other Support. Bayer and its Affiliates hereby designate Claudia Geis
as the single point of contact that Talecris may utilize to coordinate
transitional issues for Europe. This point of contact shall provide reasonable
assistance to Talecris in support of its efforts to secure from Bayer,
B.Biologicals or Distributors data or other information reasonably needed to
allow Talecris to complete the transition of Distribution activities from
Distributors to Talecris.

 

13.                                 Rosia.
For the avoidance of doubt, the Rosia Phase I Agreement shall remain in full
force and effect.

 

14.                                 Bayer
Guaranty. Bayer hereby agrees to (i) cause each Distributor to duly execute
and deliver an original copy of Exhibit K to this Amendment to Talecris.
(ii) prior to the time any Distributor becomes a party to this Amendment by
executing and delivering Exhibit K to Talecris, cause each Distributor
to take any and all actions required by such Distributor under this Amendment,
as if such Distributor was a party hereto, and (iii) prior to the time any
Distributor becomes a party to this Amendment by executing and delivering Exhibit
K to Talecris, assume the indemnification obligations of such Distributor
pursuant to Article 16 of the Original Agreement as such provision applies to
this Amendment, as if such Distributor was a party hereto.

 

15.                                 Insurance.
Talecris maintains the product liability insurance coverage set forth at
Exhibit L hereto. Talecris represents and warrants that such insurance is in
full force and effect and covenants that such insurance will remain in full
force and effect. Upon execution of this Agreement, Talecris shall cause Bayer
and its Affiliates acting as Distributors hereunder to become additional
insureds thereto and shall provide Bayer evidence thereof. The covenants
contained herein shall survive indefinitely.

 

16.                                 Parties
In Interest. The Original Agreement and this Amendment and all of the
provisions thereof shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and assigns, and it is not
intended to confer upon any other person any rights or remedies other than
persons eligible for indemnification in accordance with Section 11.

 

17.                                 Miscellaneous.
All other provisions of the Original Agreement shall continue in accordance
with the provisions of the Original Agreement. Each Party shall be responsible
for all fees, costs, and expenses incurred by it in connection with the
negotiation and execution of this Amendment.

 

3

 

* 
*  *

 

[Signature Page Follows]

 

4

 

IN WITNESS
WHEREOF, the Parties have caused this Amendment to be
signed by their respective officers thereunto duly authorized, all as of the
date first written above.

 

	
   

  	
  TALECRIS BIOTHERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
  BAYER BIOLOGICALS S.R.L.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  

 

Bayer
Healthcare LLC is signing this Amendment solely to evidence its agreement that
it will meet the obligations in Section 14 of this Amendment or any other
provision of this Amendment or the Original Agreement where performance of this
Amendment or the Agreement would require Bayer to take some action.

 

	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]